Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | POLG | P54098 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20774171 | 0.85 | P2RX7 (0.49) | HSP90AB1HSP90AA1P2RX7ABCB11POLA1 | |
| SCHEMBL3730211 | 0.84 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL21282838 | 0.76 | CDK1 (0.46) | HSP90AB1HSP90AA1P2RX7 | |
| SCHEMBL31599667 | 0.71 | FGFR1 (0.41) | ABCB11POLA1POLGFAPSLC22A6 | |
| SCHEMBL7672450 | 0.71 | PNP (0.63) | — | |
| SCHEMBL10364108 | 0.70 | ACHE (0.40) | HDAC6HDAC1HDAC4 | |
| SCHEMBL11082532 | 0.68 | ABCB11 (0.45) | ABCB11POLA1POLGFAPSLC22A6 | |
| SCHEMBL21282810 | 0.68 | CDK1 (0.47) | HSP90AB1HSP90AA1 | |
| SCHEMBL2780215 | 0.68 | PNP (0.43) | — | |
| SCHEMBL16510025 | 0.67 | POLB (0.42) | ABCB11POLA1POLGFAPSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| EP-1794162-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006031505-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | HSP90AB1 3062/4885HSP90AA1 2331/4885P2RX7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.